Relationship between the Occurrence of Thromboembolism and INR Measurement Interval in Low Intensity Anticoagulation after Aortic Mechanical Valve Replacement |
Rhie, Sang-Ho
(Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Choi, Jun-Young (Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University) Jang, In-Seok (Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University) Kim, Jong-Woo (Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University) Lee, Chung-Eun (Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University) Park, Hyun-Oh (Department of Thoracic and Cardiovascular Surgery, College of Medicine and Institute of Health Sciences, Gyeongsang National University) |
1 | Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994;107:1136-45. |
2 | Kim CW, Kim YT. Anticoagulation Management after Mitral Valve Replacement with the St. Jude Medical Prosthesis. Korean J Thorac Cardiovasc Surg 1998;31:1172-82. |
3 | Jeong SC, Kim MJ, Song CM, Kim WS, Shin YC, Kim BY. Low-intensity oral anticoagulation versus high-intensity oral anticoagulation in patients with mechanical bileaflet prosthetic heart valves. Korean J Thorac Cardiovasc Surg 2008;41:430-8. |
4 | Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physician. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):110S-2S. DOI |
5 | Kim JW, Rhie SH, Kim YC, Yang JH, Jang IS, Choi, JY. Acceptability of low intensity anticoagulation therapy after mechanical heart valve replacement. Korean J Thorac Cardiovasc Surg 2009;42:193-200. |
6 | Lidstone V, Janes S, Stross P. INR: Intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol 2000;22:291-3. DOI ScienceOn |
7 | Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg 2005;79:776-82. discussion 782-3. DOI ScienceOn |
8 | Tominaga R, Kurisu K, Ochiai Y, et al. A 10-year experience with the Carbomedics cardiac prosthesis. Ann Thorac Surg 2005;79:784-9. DOI ScienceOn |
9 | Spiliopoulos K, Haschemi A, Parasiris P, Kemkes BM. Sorin BicarbonTM bileaflet valve: a 9.8-year experience. Clinical performance of the prosthesis after heart valve replacement in 587 patients. Interact Cardiovasc Thorac Surg 2008;20. [Epub ahead of print] |
10 | Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am Heart J 2010;160:171-8. DOI ScienceOn |
11 | Aagaard J, Tingleff J. Fifteen years' clinical experience with the CarboMedics prosthetic heart valve. J Heart Valve Dis 2005;14:82-8. |
12 | Anonymous (1983). "33: Expert Committee on Biological Standardization. Requirements for thromboplastins and plasma used to control oral anticoagulant therapy". World Health Organ Tech Rep Ser. pp. 81-105. |
13 | Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987;44:430-45. DOI ScienceOn |
14 | Ikonomidis JS, Kratz JM, Crumbley AJ 3rd, et al. Twenty-year experience with the St Jude Medical mechanical valve prosthesis. J Thorac Cardiovasc Surg 2003;126:2022-31. DOI ScienceOn |
15 | Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996;89:127-35. DOI ScienceOn |
16 | Butchart EG, Lewis PA, Grunkemeier GL, Kulatilake N, Breckenridge IM. Low risk of thrombosis and serious embolic events despite low-intensity anticoagulation. Experience with 1,004 Medtronic Hall valves. Circulation 1988;78(3 Pt 2):I66-77. |
17 | Gan GG, Teh A, Goh KY, Chong HT, Pang KW. Racial background is a determinant factor in the maintenance dosage of warfarin. Int J Hematol 2003;78:84-6. DOI ScienceOn |
18 | You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005;59:582-7. DOI ScienceOn |
19 | Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39:1008-12. [Epub 2005 Apr 26] DOI ScienceOn |